Geona Guappone, APRN
Nurse Practitioner · Alliance, OHNPI 1932857075
Payments from drug & device makers
Across 134 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$670
- Pfizer$344
- Lilly USA, LLC$240
- Novo Nordisk$204
- Boehringer Ingelheim$95
- Merck$62
- plus $472 from 18 others
What the payments were for
- Food & beverage$2,086100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $670 |
| Pfizer | 35 | $344 |
| Lilly USA, LLC | 18 | $240 |
| Novo Nordisk | 12 | $204 |
| Boehringer Ingelheim | 6 | $95 |
| Merck | 4 | $62 |
| AbbVie | 3 | $62 |
| Axsome Therapeutics, Inc. | 2 | $58 |
| Bayer | 3 | $45 |
| Exact Sciences | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Radius Health, Inc. | 2 | $34 |
| Viatris Specialty LLC | 1 | $23 |
| Pulmonx Corporation | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Athena Bioscience, LLC | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| GSK | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
How this compares
$2,086 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $27,303 |
| EliquisApixaban | 39 | $23,817 |
| JardianceEmpagliflozin | 23 | $22,033 |
| OzempicSemaglutide | 19 | $19,935 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $13,792 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $2,488 |
| Rosuvastatin Calcium | 31 | $1,331 |
| Methylprednisolone | 237 | $1,245 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,217 |
| Ventolin HfaAlbuterol Sulfate | 17 | $920 |
| Amlodipine Besylate | 106 | $627 |
| Valsartan | 13 | $545 |
| Pregabalin | 27 | $470 |
| Omeprazole | 57 | $430 |
| Ondansetron OdtOndansetron | 26 | $382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $204 | $33,72731 claims |
| GSKTrelegy Ellipta | $14 | $27,30333 claims |
| PfizerEliquis | $344 | $23,81739 claims |
| Boehringer IngelheimJardiance | $95 | $22,03323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Alliance
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.